DelveInsight’s “Diabetic Peripheral Neuropathy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Diabetic Peripheral Neuropathy Market with DelveInsight’s In-Depth Report @ Diabetic Peripheral Neuropathy Market Size
Key Takeaways from the Diabetic Peripheral Neuropathy Market Report
Stay ahead in the Diabetic Peripheral Neuropathy Therapeutics Market with DelveInsight’s Strategic Report @ Diabetic Peripheral Neuropathy Market Outlook
Diabetic Peripheral Neuropathy Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends @ Diabetic Peripheral Neuropathy Prevalence
Diabetic Peripheral Neuropathy Marketed Drugs
QUTENZA (capsaicin), developed by Grünenthal and Averitas Pharma, is an 8% topical system that contains capsaicin in a localized dermal delivery system. Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. In July 2020, Grünenthal’s US subsidiary Averitas Pharma received US FDA approval for a QUTENZA (capsaicin) 8% patch for treating neuropathic pain associated with Diabetic Peripheral Neuropathy of the feet in adults.
TARLIGE (mirogabalin besylate) is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain, including diabetic Peripheral Neuropathic pain and postherpetic neuralgia. In January 2019, Daiichi Sankyo announced the approval of TARLIGE for marketing in Japan for the treatment of Diabetic Peripheral Neuropathy and expects the drug to benefit patients in Japan by providing a new therapeutic option for the treatment of Peripheral Neuropathy Pain.
Diabetic Peripheral Neuropathy Emerging Drugs
Engensis (VM202), developed by Helixmith is a DNA-based drug designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, this drug enters a small portion of the surrounding muscle cells. In the case of Diabetic Peripheral Neuropathy, it has the potential to reverse the underlying cause of neuropathy through an angio-neurorestorative effect, without simply managing the pain. This drug is currently in Phase III developmental stage and has been granted RMAT (Regenerative Medicine Advanced Therapy) designation by the US FDA in 2018.
VX-548 being developed by Vertex Pharmaceuticals is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain and multiple pain indications including acute pain, and neuropathic pain. It is currently in Phase III development stage.
Get In-Depth Knowledge on Diabetic Peripheral Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Peripheral Neuropathy Treatment Market
Diabetic Peripheral Neuropathy Market Outlook
Treatment modalities focus on optimized diabetic management and symptomatic relief. Glycemic control is the first step in the approach to disease management and has been shown to improve the occurrence of falls and the presence of foot ulcers. The three main principles of treatment for peripheral neuropathy are glycemic control, foot care, and pain management. The prescription medicines commonly used for managing diabetic peripheral neuropathy pain include Gabapentin and Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Opioids. Other Alternatives include Antiseizure Medications like carbamazepine or lamotrigine.
Diabetic Peripheral Neuropathy Drugs Uptake
Suzetrigine (VX-548), under development by Vertex Pharmaceuticals, holds promise as a potential game-changer in the treatment landscape of diabetic peripheral neuropathy. Positioned as an oral, selective NaV1.8 inhibitor, Suzetrigine boasts high selectivity for NaV1.8 over other NaV channels, enhancing its therapeutic potential. Its Phase III development stage underscores its advancement towards market entry. The oral route of administration offers a distinct advantage, ensuring ease of uptake for patients compared to alternative pipeline drugs. Moreover, Suzetrigine’s mechanism of action aligns with addressing neuropathic pain effectively.
Unlock Strategic Insights with DelveInsight’s Comprehensive Diabetic Peripheral Neuropathy Market Report @ Diabetic Peripheral Neuropathy Market Drivers and Barriers
Scope of the Diabetic Peripheral Neuropathy Market Report
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Diabetic Peripheral Neuropathy Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management
9 Epidemiology and Patient Population of Diabetic Peripheral Neuropathy in the 7MM
10 Patient Journey
11 Marketed Therapies
Full list of marketed drugs will be provided in the report
12 Emerging Therapies
Full list of emerging drugs will be provided in the report
13 Diabetic Peripheral Neuropathy: 7MM Market Analysis
14 Unmet Needs
15 SWOT Analysis
16 KOL Views
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/case-study/in-licensing-opportunity
